Skip to content
OpenCapital
Get started

Amylyx Pharmaceuticals, Inc. AMLX Milestone Payments Related To In Process Research And Development

Other financials

Income statement

See full
Revenue-—
Gross profit-—
Operating income-$43.8M-15.8%
Net income-$41.3M-15.0%
EPS (diluted)-$0.37+11.9%

Balance sheet

See full
Cash & equivalents$229.1M+283%
Total debt$5.6M+307%
Total equity$273.2M+35.6%
Total assets$293.6M+33.7%

Cash flow

See full
Operating cash flow-$36.9M+7.4%
CapEx$86.0K+330%
Free cash flow-$28.0M+52.6%

Valuation

See full
Market cap$1.89B+390%

Profitability

See full
Gross margin100%+6.9pp
Operating margin-47,349.8%-47,409pp
Net margin-45,096.2%-45,152pp
FCF margin-39,826.7%-39,847pp

Returns & leverage

See full
Return on equity-63.3%-12.2pp
Debt / equity0×0.0×
Current ratio17.9×+5.8×

Where this comes from

Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept amlx:MilestonePaymentsRelatedToInProcessResearchAndDevelopment.

The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Amylyx Pharmaceuticals, Inc.'s milestone payments related to in process research and development?
Amylyx Pharmaceuticals, Inc. (AMLX) reported milestone payments related to in process research and development of $4M in Q1 2026.